METHODS FOR INDUCING EPITHELIAL CANCER CELL SENESCENCE

• US 20130324479A1
• Filed: 08/09/2013
• Published: 12/05/2013
• Est. Priority Date: 02/10/2011
• Status: Abandoned Application

• Current Assignee: The Institute for Cancer Research (Fox Chase Cancer Center)
• Original Assignee: The Institute for Cancer Research (Fox Chase Cancer Center)
• Inventors: Zhang, Rugang, Bitler, Benjamin
• Application Number:
  US13/963,031
• Publication Number:
  US 20130324479A1
• Time in Patent Office: Days
• US Class Current: 514/19.3
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/57449 of ovaries

Abstract

Systems, methods, and computer readable media for diagnosing or characterizing epithelial cancer or its stages based on the level of expression of the Wnt5a gene or protein are provided. The level of nucleic acids encoding Wnt5a or the level of Wnt5a protein is measured in a tissue sample, and the level is compared with reference values. Methods for inducing senescence of an epithelial cancer cell are also provided.

Claims

1. A method for determining the prognosis of an epithelial ovarian cancer patient, comprising:

(a) determining the level of expression of a nucleic acid encoding Wnt5a in a tissue sample obtained from the patient, or (b) determining the concentration of Wnt5a protein in a tissue sample obtained from the patient;

(c) comparing the level of expression determined according to step (a) with one or more reference values comprising a Wnt5a nucleic acid expression level that is lower than the Wnt5a nucleic acid expression level in a subject that does not have epithelial ovarian cancer and that is indicative of a poor prognosis for epithelial ovarian cancer, using a processor programmed to compare the level of expression determined according to step (a) with the reference values, or

(d) comparing concentration of Wnt5a protein determined according to step (b) with one or more reference values comprising a Wnt5a protein expression level that is lower than the Wnt5a protein expression level in a subject that does not have epithelial ovarian cancer and that is indicative of a poor prognosis for epithelial ovarian cancer; and

,

(e) determining the prognosis of the patient based on the comparison.

2. The method of claim 1, wherein the nucleic acid encoding Wnt5a is an mRNA or a cDNA obtained from mRNA.

3. The method of claim 1, wherein the tissue sample comprises epithelial cells from an ovary of the patient.

4. The method of claim 1, wherein the prognosis comprises a substantial likelihood of mortality within about five years.

5. The method of claim 1, wherein the prognosis comprises a substantial likelihood of mortality within about ten years.

6. The method of claim 1, wherein the prognosis comprises a substantial likelihood of mortality within about one year.

7. The method of claim 1, further comprising (f) treating the patient with a regimen capable of improving the prognosis of a patient having epithelial ovarian cancer.

8. The method of claim 7, wherein the regimen comprises one or more of surgery, radiation therapy, proton therapy, ablation therapy, hormone therapy, chemotherapy, immunotherapy, stem cell therapy, follow up testing, diet management, vitamin supplementation, nutritional supplementation, exercise, physical therapy, prosthetics, transplantation, reconstruction, psychological counseling, social counseling, education, and regimen compliance management.

9. The method of claim 7, wherein the regimen comprises enhancing the expression of the Wnt5a gene in the patient.

10. The method of claim 9, wherein enhancing the expression comprises administering to the subject an effective amount of a compound that enhances the expression of the Wnt5a gene.

11. The method of claim 7, wherein the regimen comprises administering to the patient a therapeutically effective amount of the Wnt5a protein, or biologically active fragment thereof.

12. The method of claim 11, wherein the biologically active fragment of the Wnt5a protein has the amino acid sequence of SEQ ID NO:

2.

13. The method of claim 7, further comprising (g) repeating steps (a)-(f) after a period of time.

14. The method of claim 13, wherein the period of time is about six months.

15. The method of claim 13, wherein the period of time is about one year.

16. A method for inducing senescence in an epithelial ovarian cancer cell having a reduced level of expression of Wnt5a protein, comprising enhancing the expression of the Wnt5a gene in the epithelial ovarian cancer cell to a level of expression that causes one or more of activation of the HIRA pathway in the cell, antagonism of the Wnt canonical signal pathway in the cell, or antagonism of beta-catenin signaling in the cell such that senescence is induced in the cell as a result of one or more of the activation of the HIRA pathway in the cell, the antagonism of the Wnt canonical signal pathway in the cell, or the antagonism of beta-catenin signaling in the cell.

17. The method of claim 16, wherein the method is carried out in vitro.

18. A method for inducing senescence in an epithelial ovarian cancer cell having a reduced level of expression of Wnt5a protein, comprising contacting the epithelial ovarian cancer cell with an amount of Wnt5a protein, or biologically active fragment thereof, sufficient to increase the level of the Wnt5a protein in the cell to cause one or more of activation of the HIRA pathway in the cell, antagonism of the Wnt canonical signal pathway in the cell, or antagonism of beta-catenin signaling in the cell such that senescence is induced in the cell as a result of one or more of the activation of the HIRA pathway in the cell, the antagonism of the Wnt canonical signal pathway in the cell, or the antagonism of beta-catenin signaling in the cell.

19. The method of claim 18, wherein the method is carried out in vitro.

20. The method of claim 18, wherein the biologically active fragment of the Wnt5a protein has the amino acid sequence of SEQ ID NO:

2.